

Michigan Pharmacy and Therapeutics Committee
Meeting of December 5, 2006
Kellogg Center, East Lansing Michigan, 6PM
DRAFT Minutes

I. Introductions and Welcome to Oregon Drug Effectiveness Review Project Staff

Committee members present: Khan Nedd, MD, Ron Bradley, DO, Jonathon Arend, PharmD, James Dillon, MD, Paul Dake, MD, Neil Dorfman, PharmD, Justus Fiechtner, MD, Giovannino Perri, MD

State staff present: Sue Moran, Director, Bureau of Medicaid Program Operations and Quality Assurance, Max Robins, DO, Debera Eggleston, MD, George Baker, MD, Jacqueline Coleman, Tom Welch

DUR Board Members present: Jonathon Henry, MD, Dawn Parsons, RPh, Steve Bernstein, MD

Oregon Drug Effectiveness Review Program invited staff present: Mark Gibson, Director, Marian McDonough, PharmD

II. Approval of Minutes of September 12, 2006 Meeting

The minutes of the September 12, 2006 meeting were approved

III. New Drug Reviews and Line Extensions

Hepa Gam B, Amitiza, Dacogen, Daytrana, Deplin, Enjuvia, Eraxis, Elaprase, Noxafil, Zolinza, Mycamine, Januvia, Nascobal, Duetact

Following review and discussion, the Committee recommended to the Department the following:

HepaGam B: add to coverage as a medical service

Amitiza: add to coverage with a maximum dispensing limit of 3 months per beneficiary; create a PDL class for this drug, under Gastrointestinal

Dacogen: add to coverage as a medical service

Daytrana: add to coverage on the PDL in the class "Drugs for ADHD" with prior authorization

Deplin: this medical food should not be added to the Michigan Pharmaceutical Product List

Enjuvia: add to coverage on the Michigan Pharmaceutical Product List

Eraxis: add to coverage as a medical service

Elaprase: add to coverage as a medical service

Noxafil: add to coverage on the PDL in the class "Antifungals-Oral" with prior authorization

Zolinza: add to coverage on the Michigan Pharmaceutical Product List

Mycamine: add to coverage as a medical service

Januvia: add to the PDL as a new class under drugs for Diabetes; set a quantity limit of no more than 100mg per day

Nascobal: add to the Michigan Pharmaceutical Product List with prior authorization

Duetact: add to the PDL in the class "Oral Hypoglycemics-Combinations"

IV. Review of Preferred Drug List Classes

Marian McDonough, PharmD made a presentation summarizing the Oregon Drug Effectiveness Review Project review of the medications used to treat ADHD. The Committee thanks her for her presentation and for the slides which were part of the packet.

Following review and discussion of the workgroup recommendations for these PDL classes, the Committee recommended to the Department the following:

Analgesics: Narcotic, Long, Intermediate, Short Acting: The Department should review the status of fentanyl transdermal system products to ensure the most cost effective use of these pharmaceuticals. As of today, there are three manufacturers. Morphine sulfate sustained release, remains the preferred agent. The Department should ensure the most cost effective use of these pharmaceuticals.

The Department should maintain the clinical edit on Actiq® to ensure appropriate use, and should use such an edit for the new drug Fentora.

Non-Steroidal Anti-Inflammatory-Cox II Inhibitors: The Department should explore a Point of Sale edit for beneficiaries who are on anti-coagulants to allow for prescriptions for Celebrex® to be paid without the necessity of formal prior authorization. If there are other edits, such as concomitant use of other nonsteroidals, which can be managed by this edit, they should be added also.

Alzheimer's Dementia: no changes to the current status of the drugs in this class

Anti-Anxiety-General: no changes to the current status of the drugs in this class

Drugs for ADHD: add Daytrana with prior authorization; consider removing Provigil from the list as it is not licensed for use in ADHD; no other changes to the status of drugs in this class

Sedative Hypnotic Non Barbiturates: no changes at this time, but the Chair will reconvene the workgroup to discuss revising recommendations for this class, particularly as it lists chloral hydrate and diphenhydramine products, and the newer sedative hypnotics

V. Setting Meeting Dates for 2007

The Committee set the following dates: **March 6, 2007; June 5, 2007; September 11, 2007; December 4, 2007. The meetings will take place at the Kellogg Center**

VI. Public Comment

The following persons made public comment:

N. Graeter, Boehringer-Ingelheim, regarding Micardis

J. Russel, PharmD, GSK, regarding Coreg

K. Craig, MD, Kos, regarding Advicor

S. Moody, PharmD, AstraZeneca, regarding Crestor, Atacand, Toprol XL

R. Elia, MD, Shire, regarding Daytrana

L. Zanetti, PharmD, Sanofi-Aventis, regarding Avapro, Avalide

W. Gibson, MD, Abbott, regarding Tricor, Tarka

J. Swengius, PharmD, Pfizer, regarding Lipitor

G. Abela, MD, MSU, regarding use of statin drugs